Core Insights - The Chinese packaging industry has a long development history and has formed a mature industrial chain, with a continuous push towards green and sustainable packaging from the "11th Five-Year Plan" to the "14th Five-Year Plan" [1][3] - The government has issued multiple policies to support the packaging industry, emphasizing its importance in the national economy and its role in sustainable development [3][9] Policy Development Timeline - The packaging industry has seen a progressive focus on green packaging from the "11th Five-Year Plan" to the "14th Five-Year Plan," with specific goals set for 2025 to establish a resource-circulating industrial system [1] - Key milestones include the promotion of green packaging materials and the establishment of a comprehensive green packaging standard system by the end of 2025 [9] National Policy Summary and Interpretation - The packaging industry is supported by national policies that encompass design, production, printing, raw material supply, and machinery manufacturing, reflecting its integral role in the economy [3][4] - Recent policies include the "Interim Regulations on Express Delivery" aimed at promoting green, reduced, and recyclable packaging, and the "Action Plan to Reduce Logistics Costs" focusing on green transformation [5][6] Specific Policy Highlights - The "Action Plan for Deepening the Green Transformation of Express Packaging" aims for a comprehensive green packaging standard system by the end of 2025, with specific targets for reducing excessive packaging and increasing the use of recyclable materials [9][10] - The "Notice on Further Strengthening the Governance of Excessive Packaging" emphasizes the need for innovation in packaging design and materials to reduce waste and promote sustainability [11][12] Local Government Policies - Various provinces have introduced policies focusing on green packaging and the reduction of excessive packaging, with specific measures to enhance governance and compliance [13][14] - For example, Zhejiang Province has implemented measures to strengthen the governance of excessive packaging, while Gansu Province has focused on developing packaging design capabilities [14][16] Industry Goals and Future Directions - The "14th Five-Year Plan" outlines key actions for the green transformation of express packaging, with provinces setting specific targets for the adoption of recyclable packaging and the reduction of plastic waste [18][21] - The overall direction is towards a more sustainable packaging industry, with an emphasis on reducing material usage and enhancing recycling capabilities across the supply chain [12][21]

Investment Rating - The investment rating for the building materials industry is "Positive" (maintained) [1] Core Viewpoints - The report highlights that the real estate market policies are continuously tightening, creating investment opportunities in building materials. Recent policies from the central bank and local governments aim to support home purchases and improve safety in construction sites, indicating a shift towards a balanced supply-demand dynamic in the real estate market [3][4] - Recommended stocks in the consumer building materials sector include Sankeshu (channel penetration and retail expansion), Dongfang Yuhong (waterproof leader with optimized operational structure), Weixing New Materials (high-quality operations with a significant retail business), and Jianlang Wujin. Beneficiary stocks include Beixin Building Materials (gypsum board leader with diversified expansion in coatings and waterproof sectors) [3] - The report also notes that the National Development and Reform Commission has issued a plan for energy conservation and carbon reduction in the cement industry, aiming to control cement clinker capacity to around 1.8 billion tons by the end of 2025, which is expected to accelerate the iteration of energy-saving and efficient equipment [3][4] Market Performance - The building materials index increased by 2.41% in the week from June 23 to June 27, 2025, outperforming the CSI 300 index, which rose by 1.95%, resulting in a 0.46 percentage point advantage [4][13] - Over the past three months, the CSI 300 index has risen by 0.88%, while the building materials index has decreased by 3.79%, indicating a 4.67 percentage point underperformance [4][13] - In the past year, the CSI 300 index has increased by 13.29%, while the building materials index has only risen by 7.19%, showing a 6.11 percentage point underperformance [4][13] Cement Sector - As of June 27, 2025, the average price of P.O42.5 bulk cement nationwide was 284.72 yuan/ton, a decrease of 4.47% month-on-month. The price trends varied by region, with Northeast China seeing a significant drop of 21.95% [6][24] - The clinker inventory ratio reached 69.36%, an increase of 1.27 percentage points from the previous month [6][25] Glass Sector - The report indicates that the spot price of float glass as of June 27, 2025, was 1200.53 yuan/ton, reflecting a slight increase of 0.13%. The inventory of float glass decreased by 2.51%, with a total of 59 million weight boxes [6][75] - The average price of photovoltaic glass was 120.70 yuan/weight box, down by 3.44% [6][78] Fiberglass Sector - The report notes that the price of fiberglass remains stable, with various types of fiberglass priced between 3400 to 6600 yuan/ton depending on the type and region [6][3] Consumer Building Materials - The report tracks the prices of key raw materials for consumer building materials, noting slight fluctuations. For instance, the price of asphalt remained stable at 4520 yuan/ton, while the price of acrylic acid increased by 1.87% to 6825 yuan/ton [6][3]

Core Viewpoint - The report outlines the financial advisor's verification opinion regarding the equity change report of Shandong Pharmaceutical Glass Co., Ltd, confirming compliance with relevant laws and regulations, and the accuracy of the disclosed information [2][3][7]. Group 1: Verification of Equity Change Report - The financial advisor conducted a thorough review of the equity change report, ensuring it meets the requirements of the Securities Law and other relevant regulations [7][8]. - No false records, misleading statements, or significant omissions were found in the equity change report [3][7]. Group 2: Basic Information of Disclosing Obligors - The disclosing obligors include China International Medical Health Co., Ltd and Sinopharm International Hong Kong Co., Ltd, both of which are wholly owned subsidiaries of Sinopharm Group [5][9]. - China International Medical Health Co., Ltd has a registered capital of 500 million yuan and is a state-owned enterprise [9][10]. Group 3: Equity Structure and Control Relationships - Sinopharm International is the controlling shareholder of Sinopharm International Hong Kong, which is a wholly owned subsidiary [11][12]. - The controlling shareholder of Sinopharm International is Sinopharm Group, which has not changed in the last two years [12][14]. Group 4: Purpose of Equity Change - The equity change aims to enhance the core competitiveness of Sinopharm Group and support the development of strategic emerging industries [23][24]. - After the equity change, Sinopharm International will focus on building a world-class pharmaceutical materials industry chain [23][25]. Group 5: Financial Data of Disclosing Obligors - For the year ending December 31, 2024, China International Medical Health Co., Ltd reported total assets of 2,211,697.55 million yuan and total liabilities of 970,789.75 million yuan [16]. - Sinopharm International Hong Kong reported total assets of 279,837.80 million yuan for the same period [16].

Core Insights - The Chinese pharmaceutical industry is undergoing a new round of deep integration driven by policy guidance and market demand [1][2] - China National Pharmaceutical Group (Sinopharm) has announced acquisitions of two listed companies, Plasmed Biopharma and Shandong Pharmaceutical Glass, exemplifying recent M&A activity in the sector [1][2] Industry Trends - State-owned enterprises are becoming the main players in the M&A market, significantly altering the competitive landscape with their strong financial capabilities and resource integration skills [2][3] - Major industry players like Sinopharm, China Resources Pharmaceutical Group, and China General Technology Group are building competitive advantages across the entire supply chain through horizontal and vertical integration [2][3] Company Strategies - Sinopharm is focusing on strengthening its acquisition and integration strategies, aiming to enhance its market position in the health sector [3][4] - The acquisition of Plasmed Biopharma and Shandong Pharmaceutical Glass will allow Sinopharm to consolidate its supply chain, ensuring the safety and stability of the biopharmaceutical supply chain [4][6] Market Dynamics - The blood products sector is particularly strategic due to the limited number of licenses available since 2001, making existing licenses and plasma stations highly valuable [4][5] - Following the acquisition, Sinopharm's combined plasma collection volume from its subsidiaries is expected to exceed 4,181 tons, accounting for 31.2% of the national total [4][5] Financial Performance - Shandong Pharmaceutical Glass, as a leading player in the pharmaceutical glass sector, reported a revenue of 5.125 billion and a net profit of 943 million in 2024, marking 12 consecutive years of growth [5][6] Future Outlook - The M&A trend in the pharmaceutical industry is expected to evolve towards integrated supply chain acquisitions, cross-border expansions, and innovative ecosystem constructions [7]

中信证券股份有限公司 （广东省深圳市福田区中心三路8号卓越时代广场（二期）北座） 二〇二五年六月 财务顾问 山东省药用玻璃股份有限公司 详式权益变动报告书 关于 之 财务顾问核查意见 | क्रिया | | --- | | 财务顾问意见 41 | | --- | 中信证券股份有限公司关于山东省药用玻璃股份有限公司详式权益变动报告书之财务顾问核查意见 声明 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司收 购管理办法》《公开发行证券的公司信息披露内容与格式准则第15号——权益 变动报告书》《公开发行证券的公司信息披露内容与格式准则第16号——上市 公司收购报告书》及相关法律、法规的规定，中信证券股份有限公司按照证券 行业公认的业务标准、道德规范和勤勉尽责精神，就本次信息披露义务人披露 的《山东省药用玻璃股份有限公司详式权益变动报告书》进行核查，并出具核 查意见。 为使相关各方恰当地理解和使用本核查意见，本财务顾问特别声明如下： 1、本财务顾问已按照规定履行了尽职调查义务，对信息披露义务人披露的 《山东省药用玻璃股份有限公司详式权益变动报告书》进行了核查，确信内容 与格式符合规定，并保证所发表的 ...

Core Viewpoint - The report outlines the equity changes of Shandong Pharmaceutical Glass Co., Ltd. (stock code: 600529) and the involvement of China International Medical and Health Co., Ltd. and Sinopharm International Hong Kong Co., Ltd. in the investment and control of the company [1][2]. Group 1: Equity Changes - The equity change has been approved by the decision-making bodies of Luzhong Investment, Sinopharm International, and Sinopharm Group's board of directors [2]. - The equity change requires further approval from the relevant state-owned asset supervision authorities and the State Council's State-owned Assets Supervision and Administration Commission [2]. - The transaction will result in Sinopharm International controlling Luzhong Investment, thereby indirectly holding a 15% stake in Shandong Pharmaceutical Glass, changing the actual controller from Yiyuan County Finance Bureau to Sinopharm Group [4]. Group 2: Information Disclosure Obligations - The report confirms that the information disclosure obligations have been fully met according to the relevant laws and regulations, ensuring no false records or misleading statements exist [2][4]. - The report specifies that no other parties have been authorized to provide information or explanations not included in the report [2]. Group 3: Company Overview - Shandong Pharmaceutical Glass Co., Ltd. is listed on the Shanghai Stock Exchange and specializes in pharmaceutical glass products [1]. - The report includes detailed information about the controlling shareholders and the corporate structure of the involved parties, including their registered capital and business scope [5][6]. Group 4: Financial Overview - Sinopharm International's recent financial data shows total assets of approximately 2,211.70 million and total liabilities of about 970.79 million as of December 31, 2024 [9]. - The revenue for Sinopharm International was approximately 2,048.48 million, with a net profit of around 34.55 million for the same period [9].

山东省药用玻璃股份有限公司 详式权益变动报告书 上市公司名称：山东省药用玻璃股份有限公司 股票简称：山东药玻 股票代码：600529 股票上市地点：上海证券交易所 信息披露义务人一：中国国际医药卫生有限公司 住所及通讯地址：北京市朝阳区惠新东街 4 号 信息披露义务人二：国药国际香港有限公司 住所及通讯地址：香港湾仔轩尼诗道 288 号英皇集团中心 1601 室 签署日期：二〇二五年六月 山东省药用玻璃股份有限公司详式权益变动报告书 信息披露义务人声明 一、本报告书系根据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司收购管理办法》《公开发行证券的公司信息披露内容与格式准则第 15号——权益变动报告书》《公开发行证券的公司信息披露内容与格式准则第 16号——上市公司收购报告书》及其他相关法律、法规及部门规章的有关规定 编写。 二、依据《中华人民共和国证券法》《上市公司收购管理办法》的规定， 本报告书已全面披露了信息披露义务人（及其一致行动人）在山东省药用玻璃 股份有限公司拥有权益的股份变动情况。截至本报告书签署日，除本报告书披 露的信息外，信息披露义务人没有通过任何其他方式在山东省药用玻璃股份有 ...

Group 1 - China National Pharmaceutical Group Corporation (Sinopharm Group) is set to become the controlling shareholder of Shandong Pharmaceutical Glass (Shandong Yaobo) through a capital increase of 2.449 billion yuan, acquiring 51% of the shares in Luzhong Investment [1][2] - Following the completion of this transaction, Sinopharm Group will indirectly control 19.5% of Shandong Yaobo's total shares, changing the actual controller from the Yiyuan County Finance Bureau to Sinopharm Group [2][6] - Shandong Yaobo has shown consistent growth, with revenue and net profit increasing for 12 consecutive years since 2013, with overall growth rates of 249% and 686% respectively [1][5] Group 2 - The partnership aims to enhance the industrial chain and modernize the manufacturing system, aligning with national strategies for technological innovation and industry control [4] - Sinopharm Group, as the largest state-owned pharmaceutical enterprise in China, will leverage its resources to empower Shandong Yaobo in technology, funding, and distribution channels [6] - Shandong Yaobo has established a comprehensive product line and maintains long-term collaborations with major pharmaceutical companies, indicating its strong market position [5][6] Group 3 - In 2024, Shandong Yaobo reported a revenue of 5.125 billion yuan, a year-on-year increase of 2.87%, and a net profit of 943 million yuan, up 21.55% [5] - The company has been actively expanding its international market presence, with foreign revenue accounting for 28.72% of total revenue in 2024, reflecting an 8.29% increase [5][6] - The restructuring is part of a broader trend of Sinopharm Group's recent activities in the A-share market, indicating a strategic focus on consolidating its position in the pharmaceutical industry [3]

Core Viewpoint - The recent investment cooperation agreement between China National Pharmaceutical Group (国药集团) and Shandong Pharmaceutical Glass Co., Ltd. (山东药玻) marks a significant shift in the company's ownership structure, potentially enhancing its operational capabilities and market position in the pharmaceutical packaging industry [1][3]. Company Overview - Shandong Pharmaceutical Glass, established in 1970 and listed in June 2002, has developed a comprehensive range of pharmaceutical packaging products, including bottles, stoppers, and caps, becoming a leading manufacturer in the industry [5]. - In Q1 2025, the company reported revenues of 1.242 billion yuan and a net profit attributable to shareholders of 224 million yuan [5]. Investment Details - On June 20, 2023, an investment cooperation agreement was signed, where China National Pharmaceutical Group and its subsidiaries will inject 2.449 billion yuan into Shandong Pharmaceutical Glass's indirect controlling shareholder, Shandong Luzhong Investment Co., Ltd. (鲁中投资), acquiring a 51% stake [1]. - This transaction will change the indirect controlling shareholder from Luzhong Holdings to China National Pharmaceutical Group, with the actual controller shifting from the Yiyuan County Finance Bureau to China National Pharmaceutical Group [1]. Strategic Implications - The partnership aims to enhance the modernization of the industrial system and improve the competitiveness of the pharmaceutical and health industry in Yiyuan County and Zibo City [3]. - The acquisition is seen as a strategic move for China National Pharmaceutical Group to expand its presence in the upstream pharmaceutical supply chain, particularly in the pharmaceutical packaging materials sector [3][5]. Challenges and Opportunities - Despite steady growth, Shandong Pharmaceutical Glass faces challenges such as the need for capital, technology, and management upgrades to further its development [4]. - The collaboration with China National Pharmaceutical Group is expected to provide substantial financial support, access to global marketing networks, and technological advancements, which could significantly enhance the company's competitive edge and contribute to the growth of the local pharmaceutical industry [5].

Core Viewpoint - Shandong Pharmaceutical Glass Co., Ltd. is experiencing a decline in stock price and has a lower PE ratio compared to the industry average, indicating potential undervaluation in the medical device sector [1][2]. Company Summary - Shandong Pharmaceutical Glass closed at 22.17 yuan, down 1.55%, with a rolling PE ratio of 15.55 times and a total market capitalization of 14.712 billion yuan [1]. - The company operates in the pharmaceutical glass packaging sector, focusing on the research, production, and sales of glass bottles, rubber stoppers, and bottle caps [1]. - The company has been recognized with a new provincial engineering research center and has received the title of "National Manufacturing Single Champion Enterprise," highlighting its leading position in the field [1]. - The "Key Technology and Industrialization of Pharmaceutical Glass Bottle Manufacturing" project won two prestigious industry awards, showcasing its technological innovation and industrial value [1]. Financial Performance - In the first quarter of 2025, the company reported revenue of 1.242 billion yuan, a year-on-year decrease of 1.97%, while net profit was 224 million yuan, a year-on-year increase of 1.29%, with a sales gross margin of 30.21% [1]. Industry Summary - The average PE ratio for the medical device industry is 48.89 times, with a median of 35.79 times, positioning Shandong Pharmaceutical Glass at the 37th rank within the industry [1][2]. - The company has 70,488 shareholders as of March 31, 2025, an increase of 6,223 shareholders, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1].